Skip Nav Destination
Fedratinib in myelofibrosis
Bendamustine-induced immune hemolytic anemia: a case report and systematic review of the literature
Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma
Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA
Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression
Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)
Clinical value of event-free survival in acute myeloid leukemia
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease
Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
Issue Archive
April 28 2020
In this Issue
Table of Contents
CLINICAL GUIDELINES
American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults
M. R. DeBaun,L. C. Jordan,A. A. King,J. Schatz,E. Vichinsky,C. K. Fox,R. C. McKinstry,P. Telfer,M. A. Kraut,L. Daraz,F. J. Kirkham,M. H. Murad
DRUG ADVANCES
Fedratinib in myelofibrosis
Clinical Trials & Observations
EXCEPTIONAL CASE REPORT
Bendamustine-induced immune hemolytic anemia: a case report and systematic review of the literature
Clinical Trials & Observations
STIMULUS REPORT
Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma
Clinical Trials & Observations
Sarvari V. Yellapragada,Nathanael R. Fillmore,Anna Frolov,Yang Zhou,Pallavi Dev,Hassan Yameen,Chizoba Ifeorah,Nhan V. Do,Mary T. Brophy,Nikhil C. Munshi
REVIEW ARTICLE
SYSTEMATIC REVIEW
HEMATOPOIESIS AND STEM CELLS
Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias
Clinical Trials & Observations
Xing Fan,Ronan Desmond,Thomas Winkler,David J. Young,Bogdan Dumitriu,Danielle M. Townsley,Fernanda Gutierrez-Rodrigues,Jennifer Lotter,Janet Valdez,Stephanie E. Sellers,Ma Evette Barranta,Ruba N. Shalhoub,Colin O. Wu,Maher Albitar,Katherine R. Calvo,Neal S. Young,Cynthia E. Dunbar
IMMUNOBIOLOGY AND IMMUNOTHERAPY
LYMPHOID NEOPLASIA
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA
Clinical Trials & Observations
Sarah C. Rutherford,Michael Herold,Wolfgang Hiddemann,Lale Kostakoglu,Robert Marcus,Maurizio Martelli,Laurie H. Sehn,Marek Trněný,Judith Trotman,Umberto Vitolo,Tina Nielsen,Federico Mattiello,Deniz Sahin,Gila Sellam,Peter Martin
Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression
Clinical Trials & Observations
Zachary J. Walker,Michael J. VanWyngarden,Brett M. Stevens,Diana Abbott,Andrew Hammes,Christophe Langouët-Astrie,Clayton A. Smith,Brent E. Palmer,Peter A. Forsberg,Tomer M. Mark,Craig T. Jordan,Daniel W. Sherbenou
MYELOID NEOPLASIA
Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States
Amer M. Zeidan,Nikolai A. Podoltsev,Xiaoyi Wang,Chi Zhang,Jan Philipp Bewersdorf,Rory M. Shallis,Scott F. Huntington,Natalia Neparidze,Smith Giri,Steven D. Gore,Amy J. Davidoff,Xiaomei Ma,Rong Wang
Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia
Clinical Trials & Observations
Nicholas J. Short,Keyur P. Patel,Maher Albitar,Miguel Franquiz,Rajyalakshmi Luthra,Rashmi Kanagal-Shamanna,Feng Wang,Rita Assi,Guillermo Montalban-Bravo,Jairo Matthews,Wanlong Ma,Sanam Loghavi,Koichi Takahashi,Ghayas C. Issa,Steven M. Kornblau,Elias Jabbour,Guillermo Garcia-Manero,Hagop M. Kantarjian,Zeev Estrov,Farhad Ravandi
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)
Clinical Trials & Observations
Jeffrey E. Lancet,Anna B. Moseley,Steven E. Coutre,Daniel J. DeAngelo,Megan Othus,Martin S. Tallman,Mark R. Litzow,Rami S. Komrokji,Harry P. Erba,Frederick R. Appelbaum
Clinical value of event-free survival in acute myeloid leukemia
Clinical Trials & Observations
Abhishek Maiti,Hagop M. Kantarjian,Vinita Popat,Gautam Borthakur,Guillermo Garcia-Manero,Marina Y. Konopleva,Courtney D. DiNardo,Srdan Verstovsek,Michael Andreeff,Tapan M. Kadia,Helen O. Ajufo,Rohit V. Goswamy,Carlos Blanco,Miguel Velasquez,Naval G. Daver,Naveen Pemmaraju,Sherry R. Pierce,William G. Wierda,Steven M. Kornblau,Farhad Ravandi,Jorge E. Cortes
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia
Clinical Trials & Observations
Catherine C. Smith,Mark J. Levis,Olga Frankfurt,John M. Pagel,Gail J. Roboz,Richard M. Stone,Eunice S. Wang,Paul L. Severson,Brian L. West,Mai H. Le,Sabine Kayser,Bao Lam,Henry H. Hsu,Chao Zhang,Gideon Bollag,Alexander E. Perl
RED CELLS, IRON, AND ERYTHROPOIESIS
Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia
Annelies. J. van Vuren,Michele F. Eisenga,Stephanie van Straaten,Andreas Glenthøj,Carlo A. J. M. Gaillard,Stephan J. L. Bakker,Martin H. de Borst,Richard van Wijk,Eduard J. van Beers
THROMBOSIS AND HEMOSTASIS
TRANSFUSION MEDICINE
TRANSPLANTATION
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease
Clinical Trials & Observations
Mark A. Schroeder,H. Jean Khoury,Madan Jagasia,Haris Ali,Gary J. Schiller,Karl Staser,Jaebok Choi,Leah Gehrs,Michael C. Arbushites,Ying Yan,Peter Langmuir,Nithya Srinivas,Michael Pratta,Miguel-Angel Perales,Yi-Bin Chen,Gabrielle Meyers,John F. DiPersio
Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia
Clinical Trials & Observations
Brigitte Strahm,Felicia Loewecke,Charlotte M. Niemeyer,Michael Albert,Marc Ansari,Peter Bader,Yves Bertrand,Birgit Burkhardt,Lydie M. Da Costa,Alina Ferster,Alexandra Fischer,Tayfun Güngör,Bernd Gruhn,Ina Hainmann,Friedrich Kapp,Peter Lang,Ingo Müller,Ansgar Schulz,Amina Szvetnik,Marcin Wlodarski,Peter Noellke,Thierry Leblanc,Jean-Hugues Dalle
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
Clinical Trials & Observations
Amy E. DeZern,Marianna L. Zahurak,Heather J. Symons,Kenneth R. Cooke,Gary L. Rosner,Douglas E. Gladstone,Carol Ann Huff,Lode J. Swinnen,Philip Imus,Ivan Borrello,Nina Wagner-Johnston,Richard F. Ambinder,Leo Luznik,Javier Bolaños-Meade,Ephraim J. Fuchs,Richard J. Jones,Robert A. Brodsky
COMMENTARY
ERRATUM
-
Cover Image
Cover Image
COVER FIGURE
Geographic prevalence of blood product recalls in the United States. Normalized county-level prevalence was estimated by using recall-event density, defined as the number of recall events originating in a county divided by the number of blood product establishments in that county. Counties in blue have no recall events, and counties in red have a recall-event density proportional to the shading intensity. Regions in white do not have blood product establishments. The images in circles are snippets of recalled blood product distribution (top) and recall-event likelihood (bottom). See the article by Alqemlas et al. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals